RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy. - Wikidata - wikimedia - TriplyDB

RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy.

RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy.

http://www.wikidata.org/entity/Q37333053

about

Respiratory Syncytial Virus (RSV) Modulation at the Virus-Host Interface Affects Immune Outcome and Disease Pathogenesis Induction of protective effector immunity to prevent pathogenesis caused by the respiratory syncytial virus. Implications on therapy and vaccine design Human metapneumovirus in adults Delivery of RNAi Therapeutics to the Airways-From Bench to Bedside MicroRNA regulation of human protease genes essential for influenza virus replication MicroRNA Regulation of Human Genes Essential for Influenza A (H7N9) Replication Human RGM249-derived small RNAs potentially regulate tumor malignancy Silencing disease genes in the laboratory and the clinic Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles Advances in antivirals for non-influenza respiratory virus infections.Drug delivery-mediated control of RNA immunostimulation Pharmacologic advances in the treatment and prevention of respiratory syncytial virus.Reduced Dicer expression in the cord blood of infants admitted with severe respiratory syncytial virus disease.Clinical status of duplex RNA A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus.A status report on RNAi therapeutics.Inhibition of Tulane virus replication in vitro with RNA interference.Optimizing siRNA delivery to the genital mucosa siRNA-based topical microbicides targeting sexually transmitted infections.Current progress of siRNA/shRNA therapeutics in clinical trials.Oxime ether lipids containing hydroxylated head groups are more superior siRNA delivery agents than their nonhydroxylated counterparts.Aerosol Delivery of siRNA to the Lungs. Part 2: Nanocarrier-based Delivery Systems Inhibition of HCV 5'-NTR and core expression by a small hairpin RNA delivered by a histone gene carrier, HPhA.Exploiting endocytosis for nanomedicines.Targeting RSV with vaccines and small molecule drugs.Recent advances in diagnosis, prevention, and treatment of human respiratory syncytial virus.Silencing sexually transmitted infections: topical siRNA-based interventions for the prevention of HIV and HSV Lipid-based nanotherapeutics for siRNA delivery Potential clinical applications of siRNA technique: benefits and limitations.RNA-based therapeutics: current progress and future prospects.Expert opinion in biological therapy: update on developments in lung gene transfer.Delivery systems and local administration routes for therapeutic siRNA.Platelet Activating Factor Receptor Activation Improves siRNA Uptake and RNAi Responses in Well-differentiated Airway Epithelia.Clinical translation of RNAi-based treatments for respiratory diseases.Respiratory syncytial virus: prospects for new and emerging therapeutics.Recent Advances in Developing Antiviral Therapies for Respiratory Syncytial Virus.Polymers in the Delivery of siRNA for the Treatment of Virus Infections.Respiratory syncytial virus modifies microRNAs regulating host genes that affect virus replication.Direct whole-genome deep-sequencing of human respiratory syncytial virus A and B from Vietnamese children identifies distinct patterns of inter- and intra-host evolution.The potential of anti-infectives and immunomodulators as therapies for asthma and asthma exacerbations.

P2860

Q26823449-4374172E-ED6B-41F5-BF34-7D004FBB224A Q27021304-4BEA8B4B-F267-4ABD-B096-166672E0BBB6 Q27694039-F14AD628-60F7-4280-BE59-336964BC78DD Q28067306-E3FB4971-E32C-4183-AF36-C84AB96431A4 Q28483683-E732A6CB-F0BF-4C9C-9F34-072AB9F92BAD Q28551988-ED503598-6809-4B5E-AB4E-430F6C84061B Q28681257-BF8E9CD7-8043-4970-9455-B85339F8ECB5 Q29039090-3CC50240-1753-45EF-A001-10798A7C5DAC Q29615957-F97FB25A-19D7-4871-8FE7-7B8E58A38ED6 Q30457132-635B40A5-691B-4118-BE97-592F18225F3C Q33713938-34DA78F8-AC70-495D-B3AF-F35EE9527FF0 Q33776507-4D8E24E3-565C-458E-BF4D-20DCCCB61886 Q33840252-0960A84B-0BD1-47EA-9AA3-285FD48FF707 Q33869361-3B9A1273-2802-4EFB-840B-7C83A6B37658 Q33928650-F9B40C2D-7577-46B2-9EBB-32E1694F0DE2 Q34013891-C0D5E01B-902D-48F9-9467-04A1C2626788 Q34312061-784861D8-2646-46B6-B1DD-86ED9F0F62AE Q35766249-65EB795A-ECBB-400E-A24B-447CBB35BEBB Q35766254-706B6FFE-08CE-4DB0-A917-1EDF6F465233 Q36071638-A9330137-09FD-4581-9586-5D2ABED24CC4 Q36257158-5FC9EB52-7717-470B-8451-467EC99E79E0 Q36341433-DF460CDF-130C-458C-913F-825124EE45A2 Q36953104-FBB44442-0754-42AC-8F8B-A4F76910DDE9 Q37258701-2D9E3584-88D5-431D-9119-D1EA63968E5C Q37328584-40D83862-C503-4FBD-B542-DAFAD1B2C8F1 Q37412509-D3593648-0702-4988-8F55-ABDC977588C0 Q37553822-5A5FC59A-D016-48FE-B162-E855FDDEA976 Q37670986-98E6ED79-07FC-4EDB-B701-A6BBAFE4E900 Q37801965-A632B5B6-DA12-4263-81BE-2D6FAA07B0F4 Q37979387-BAA4F480-646F-449F-A028-DE281A80E209 Q38071683-EDDCFC60-5E86-4B52-A300-8ADBFCB9C282 Q38076344-C8F5A18B-FA67-41BA-A9C9-C5013F26C977 Q38305769-5E835B27-43BA-4ABE-AABE-ED7C5EF63C7D Q38383297-A47EF62B-D3A1-4CA4-9491-5B4E13B394F1 Q38675686-34751FCE-50B7-46F3-877E-B5178A663BFA Q38742141-FF413B74-08A2-420C-8CE7-C1A0D8F29E20 Q38889573-55EAE7A0-E66B-48B9-BCB3-D7639C158D74 Q39297218-3F847F29-508A-495D-8D64-7DE5F9976D71 Q39398265-B15B8834-33FC-454D-96F8-80F507A29A43 Q39444008-DCF568EC-83AF-40FE-8E44-2445C5B2A665

P2860

RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy.

http://www.wikidata.org/entity/Q37333053

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 08 June 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

RNA interference-mediated sile ...... s a potent antiviral strategy.

@en

RNA interference-mediated sile ...... s a potent antiviral strategy.

@nl

type

label

RNA interference-mediated sile ...... s a potent antiviral strategy.

@en

RNA interference-mediated sile ...... s a potent antiviral strategy.

@nl

prefLabel

RNA interference-mediated sile ...... s a potent antiviral strategy.

@en

RNA interference-mediated sile ...... s a potent antiviral strategy.

@nl

P1433

Q37333053-581D51F6-33B4-44CE-8DB4-773863E5A533

P1476

Q37333053-95C9B71B-1861-470B-9DD4-48DC0AAD6EF0

P2093

Q37333053-0F125EF6-76F0-4F8E-818A-D8FCDA68C886

Q37333053-10C1292E-488D-4F27-8333-3DCC81FC4525

Q37333053-1A419256-4BD3-4B73-93FA-81A9C2DA4754

Q37333053-2AA34CD3-9F95-439D-9092-E172E2EEBB1D

Q37333053-30767CD3-D707-4BBC-A819-D6348199C74B

Q37333053-4000EF5F-BB8C-4708-9E23-FB254E59246D

Q37333053-4B93FF50-FC21-413D-93CF-82100B3CFBCD

Q37333053-4FEC642A-6905-4619-BCD9-5ADEE9CE3578

Q37333053-5551ADE4-20E2-4A26-BCA9-C5BCE48F41D0

Q37333053-684B3D5D-DCCC-41AD-95DC-208A4B4262EC

P2860

Q37333053-0551F90B-8748-4717-98EA-8EEC8F9DBD76

Q37333053-097E3790-D5A4-4B2C-B513-8E9E980DAA97

Q37333053-0A1C83B0-6761-4853-868D-595EFC0E8733

Q37333053-0A1EEC4C-6388-4A5A-A958-9EA938BA6A86

Q37333053-0D00129F-4017-4350-BE16-EF055114EDFE

Q37333053-0DC1BDC9-3564-4B4F-ACFC-163492109B07

Q37333053-0F91EA8B-18B2-4658-80F6-E892C3875989

Q37333053-115FA888-AB5F-4E98-A6B2-5DA7C4D0AB8A

Q37333053-118F840A-4C7A-4911-BA80-9CB79BBF0AFD

Q37333053-156B7884-D51B-48C8-90EF-09669CC2BE87

P304

Q37333053-FF67DDC9-7595-4289-903F-12B3F1352581

P31

Q37333053-417D0143-3305-4C14-93C6-A11CD716B582

P356

Q37333053-ECD4B279-91A8-4FD4-8A03-4CCA006365DC

P407

Q37333053-24C41337-AD0B-46E6-8908-476AD3206C3E

P433

Q37333053-C4324CAC-598B-4BDC-A9F4-ACD4A98CE809

P478

Q37333053-29C9481C-861A-4FB6-9B76-09EED3CC7488

P50

Q37333053-DD2BC1CC-B7FF-4C06-BE7C-FC90394CFA99

P577

Q37333053-688E128F-B7F8-4B38-A8BD-45DE275D32DA

P5875

Q37333053-33453E26-816D-4226-A01B-EE80C296CD1D

P698

Q37333053-CA6E2B10-7D32-4487-9714-416FECE3350C

P921

Q37333053-D0353D5C-E650-4F0C-84E6-3734ECADC754

P932

Q37333053-E95E6ADB-44CB-4D13-9D67-74D7D802C967

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

RNA interference-mediated sile ...... s a potent antiviral strategy.

@en

P2093

Ingo Roehl

http://www.w3.org/2001/XMLSchema#string

Ivanka Toudjarska

http://www.w3.org/2001/XMLSchema#string

Jeffrey Kahn

http://www.w3.org/2001/XMLSchema#string

John P DeVincenzo

http://www.w3.org/2001/XMLSchema#string

Lubomir Nechev

http://www.w3.org/2001/XMLSchema#string

Mark Van Ranst

http://www.w3.org/2001/XMLSchema#string

Martin Maier

http://www.w3.org/2001/XMLSchema#string

Mathias John

http://www.w3.org/2001/XMLSchema#string

Muthiah Manoharan

http://www.w3.org/2001/XMLSchema#string

Philipp Hadwiger

http://www.w3.org/2001/XMLSchema#string

P2860

Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children

Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7

Genetic variability and molecular evolution of the human respiratory syncytial virus subgroup B attachment G protein

NCBI Reference Sequence (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins

Inhibition of Respiratory Syncytial Virus Infections With Morpholino Oligomers in Cell Cultures and in Mice

Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

RNA interference

Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections

Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitro

In vivo inhibition of respiratory syncytial virus by ribavirin

P304

3952-3962

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00014-09

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-06-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26275780

http://www.w3.org/2001/XMLSchema#string

P698

19506055

http://www.w3.org/2001/XMLSchema#string

P921

P932

2737834

http://www.w3.org/2001/XMLSchema#string